NCT03834883View on ClinicalTrials.gov

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

May 21, 2024

Study Completion Date

May 23, 2024

Conditions
Long QT SyndromeAbnormalities, Drug-Induced
Interventions
DRUG

Progesterone

Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

DRUG

Ibutilide

Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval

Trial Locations (1)

46202

Indiana University, Indianapolis

All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

Purdue University

OTHER

lead

Indiana University

OTHER

NCT03834883 - Reducing the Risk of Drug-Induced QT Interval Lengthening in Women | Biotech Hunter | Biotech Hunter